candesartan has been researched along with Cardiac Diseases in 2 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated whether exaggerated BPV aggravates hypertensive cardiac remodeling and function by activating inflammation and angiotensin II-mediated mechanisms." | 7.75 | Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. ( Anegawa, T; Hirooka, Y; Ikeda, A; Imaizumi, T; Kai, H; Kajimoto, H; Kato, S; Koga, M; Kudo, H; Mifune, H; Mori, T; Takayama, N; Yasuoka, S, 2009) |
| " We investigated whether exaggerated BPV aggravates hypertensive cardiac remodeling and function by activating inflammation and angiotensin II-mediated mechanisms." | 3.75 | Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. ( Anegawa, T; Hirooka, Y; Ikeda, A; Imaizumi, T; Kai, H; Kajimoto, H; Kato, S; Koga, M; Kudo, H; Mifune, H; Mori, T; Takayama, N; Yasuoka, S, 2009) |
| "Hypoxia caused by sleep apnea might be associated with an increased risk of cardiovascular events in subjects with metabolic syndrome." | 1.33 | Angiotensin-II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia. ( Furuya, E; Hayashi, T; Inamoto, S; Kitaura, Y; Matsumura, Y; Mori, T; Nakano, D; Okuda, N; Sakai, A; Sohmiya, K; Tazawa, N; Yamashita, C, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kudo, H | 1 |
| Kai, H | 1 |
| Kajimoto, H | 1 |
| Koga, M | 1 |
| Takayama, N | 1 |
| Mori, T | 2 |
| Ikeda, A | 1 |
| Yasuoka, S | 1 |
| Anegawa, T | 1 |
| Mifune, H | 1 |
| Kato, S | 1 |
| Hirooka, Y | 1 |
| Imaizumi, T | 1 |
| Inamoto, S | 1 |
| Hayashi, T | 1 |
| Tazawa, N | 1 |
| Yamashita, C | 1 |
| Nakano, D | 1 |
| Matsumura, Y | 1 |
| Okuda, N | 1 |
| Sohmiya, K | 1 |
| Sakai, A | 1 |
| Furuya, E | 1 |
| Kitaura, Y | 1 |
2 other studies available for candesartan and Cardiac Diseases
| Article | Year |
|---|---|
Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Benzimidazoles; B | 2009 |
Angiotensin-II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |